Single-cell mutation analysis of clonal evolution in myeloid malignancies. Nature. 2020; 587(7834):477-482.
Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus. Journal of Clinical Investigation. 2017; 127(8):2957-2967.
Runx2 takes center stage in regulating HSC expansion. Blood. 2025; 146(26):3135-3136.
TTLL4 glutamyltransferase is a therapeutic target for NPM1-mutated Acute Myeloid Leukemia. Blood. 2025; 146(Supplement 1):869-869.
RAS G12 and Q61 codon mutations confer distinct disease characteristics in Acute Myeloid Leukemia and exhibit differential response to RAS(ON) inhibitor RMC-7977. Blood. 2025; 146(Supplement 1):3229-3229.
Cell-extrinsic factors contribute toward myeloid-biased expansion in Tet2-mutant clonal hematopoiesis. Experimental Hematology. 2025; 148:104816.
Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia. Leukemia. 2025; 39(1):51-63.
In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy. Cancer Cell. 2024; 42(11):1955-1969.e7.
BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Prognostically Poor Subgroup Enriched for Myelodysplasia-Related Subtypes and Distinct from Other RAS Pathway Mutant AML. Blood. 2024; 144(Supplement 1):2921.
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nature Genetics. 2024; 56(11):2434-2446.
CRISPR Dependency Screens in Primary Hematopoietic Stem Cells Identify KDM3B as a Genotype-specific Vulnerability in IDH2- and TET2-mutant Cells. Cancer Discovery. 2024; 14(10):1860-1878.
Mutation order in acute myeloid leukemia identifies uncommon patterns of evolution and illuminates phenotypic heterogeneity. Leukemia. 2024; 38(7):1501-1510.
BRAF-Mutated Acute Myeloid Leukemia (AML) Represents a Distinct, Prognostically Poor Subgroup Enriched in Myelodysplasia-Related (MR-)AML. Blood. 2023; 142(Supplement 1):1575.
Chronic inflammation can transform the fate of normal and mutant hematopoietic stem cells. Experimental Hematology. 2023; 127:8-13.
Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Science Advances. 2023; 9(38):eadg0488.
Abstract A49: Characterizing the order of mutation acquisition in acute myeloid leukemia using large-scale single-cell sequencing. Blood Cancer Discovery. 2023; 4(3_Supplement):a49-a49.
Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. Clinical Cancer Research. 2023; 29(5):943-956.
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia. American Journal of Hematology. 2023; 98(1):79-89.
Cell origin-dependent cooperativity of mutant Dnmt3a and Npm1 in clonal hematopoiesis and myeloid malignancy. Blood advances. 2022; 6(12):3666-3677.
Multi-Recombinase Mouse Models of Flt3-Driven Leukemia Identifies Distinct Trajectories of Mutational Cooperativity and Leukemic Transformation. Blood. 2021; 138(Supplement 1):2220.
Clonotype-Immunophenotype Relationships in TET2 and IDH-Mutant Myeloid Transformation. Blood. 2021; 138(Supplement 1):373.
A CRISPR Activation Screen Identifies an Atypical Rho GTPase That Enhances Zika Viral Entry. Viruses. 2021; 13(11).
3004 – GENETIC APPROACHES FOR MODELING SUBCLONAL MUTATIONS IN ACUTE MYELOID LEUKEMIA. Experimental Hematology. 2021; 100:s45.
1008 – ROLE OF SEQUENTIAL MUTATIONAL ACQUISITION IN CLONAL HEMATOPOIESIS AND EVOLUTION TO AML. Experimental Hematology. 2021; 100:s20.
Abstract 99: Evolution of OncoKB, a precision oncology knowledgebase. Cancer Research. 2021; 81(13_Supplement):99-99.
N-Linked Glycosylation on Anthrax Toxin Receptor 1 Is Essential for Seneca Valley Virus Infection. Viruses. 2021; 13(5).
TMEM41B Is a Pan-flavivirus Host Factor. Cell. 2021; 184(1):133-148.e20.